Index founds Mind-NRG with $13.8M investment

Index Ventures says that Switzerland-base Mind-NRG has opened its doors with a Series A financing of €10 million ($13.8 million). Mind-NRG is developing NRG-101, a peptidic neurotrophic factor that crosses the blood-brain barrier by a receptor-mediated transport to reach its target. The compound was discovered by Germany's ProteoSys, but the company assigned development to Mind in exchange for equity in the new company.

NRG-101 is being explored for neurological and psychiatric disorders such as Parkinson's disease, Alzheimer's disease and schizophrenia.  "The preliminary experiments with NRG-101 in relevant pre-clinical models of neurodegeneration show unprecedented results in cognition improvement and restoration of the neural architecture," noted Kings College London and adviser Peter Jenner. Mind-NRG will initially focus on conducting pivotal in vitro and in vivo experiments.

- here's the release for more

Suggested Articles

The data, from two patients with severe blood disorders, are "promising” for what could be a one-and-done treatment, Cantor Fitzgerald analysts wrote.

The fund will back pharma companies as well as developers of medtech products and providers of outsourced services.

The money will fund work to develop polymers in multiple indications and an associated U.S. expansion.